title: Enhancement of depressed lymphokine activated killer cell activity in patients with hepatocellular carcinoma.
abstract: Hepatocellular carcinoma (HCC) patients can be divided into two groups according to the degree of lymphokine activated killer (LAK) cell activity; a high LAK activity group (H-LAK-HCC) and a low LAK activity group (L-LAK-HCC). Interferon-gamma (IFN-gamma) production is severely defective in L-LAK-HCC but not defective in H-LAH-HCC. IFN-gamma production is suppressed with the addition of anti-Tac in dose dependent manner, though LAK activity is suppressed only in the presence of high concentration of anti-Tac. LAK activity is suppressed with the addition of anti-IFN-gamma, which is most prominent when the antibody is present during the first 12 hr of incubation. LAK generation is enhanced with the addition of recombinant IFN-gamma, which is most prominent when it is present during the first 12 hr of incubation. However, this enhancing effect is less prominent in L-LAK-HCC as compared to normals, liver cirrhosis, and H-LAK-HCC. This enhancement is regarded to depend on the presence of Leu7+ and Leu11+ subset, as this enhancement is abandoned and IFN-gamma production is inhibited when either of these subsets is deleted. These data suggest that IFN-gamma production and the participation of Leu7+ and Leu11+ subsets is important in sufficient LAK generation, and that poor IFN-gamma production and insufficient response to IFN-gamma may be the cause of severely defective LAK generation in L-LAK-HCC.
authors.affiliation: First Department of Medicine, Kochi Medical School, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Saibara
authors.forename: S
authors.initials: S
authors.lastname: Onishi
authors.forename: Y
authors.initials: Y
authors.lastname: Matsuura
authors.forename: M
authors.initials: M
authors.lastname: Fujikawa
authors.forename: H
authors.initials: H
authors.lastname: Sakaeda
authors.forename: Y
authors.initials: Y
authors.lastname: Matsunaga
authors.forename: Y
authors.initials: Y
authors.lastname: Yamamoto
mesh_terms: D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000276:immunology / Q000378:metabolism* / Q000628:therapy; D005260:Female; D006367:HeLa Cells; D006801:Humans; D007371:Interferon-gamma / Q000037:antagonists & inhibitors / Q000096:biosynthesis* / Q000276:immunology / Q000494:pharmacology; D007376:Interleukin-2 / Q000494:pharmacology* / Q000627:therapeutic use; D015979:Killer Cells, Lymphokine-Activated / Q000187:drug effects / Q000276:immunology / Q000378:metabolism*; D008103:Liver Cirrhosis / Q000276:immunology / Q000378:metabolism; D008113:Liver Neoplasms / Q000276:immunology / Q000378:metabolism* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000494:pharmacology
chemical_list: D007376:Interleukin-2; D011994:Recombinant Proteins; D007371:Interferon-gamma